As per DelveInsight’s assessment, globally, about 6+ key pharma and biotech companies are working on 6+ pipeline drugs in the Metachromatic Leukodystrophy (MLD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
“Metachromatic Leukodystrophy (MLD) Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metachromatic Leukodystrophy Therapeutics Market.
The report provides a detailed description of the emerging drugs, including their type, stage, Mechanism of Action (MoA), Route of Administration (RoA), molecule type, inactive pipeline products, and NDA approvals.
The report also covers in-depth commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed phase. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
The report provides insights into:
- The report provides detailed insights about companies that are developing therapies in the Metachromatic Leukodystrophy Market.
- It accesses the different therapeutic candidates segmented into early-stage (phase I), mid-stage (phase II), and late-stage (phase III) development.
- It assesses the targeted drug therapeutics development with respective active and inactive (dormant or discontinued) projects.
- The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metachromatic Leukodystrophy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
On June 08, 2022, Passage Bio, Inc. (Nasdaq: PASG) announced clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PBML04, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of Metachromatic Leukodystrophy (MLD).
DelveInsight’s Report covers around 6+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Learn How the Ongoing Clinical & Commercial Activities will Affect the Metachromatic Leukodystrophy Therapeutic Segment:
There are approx. 6+ key companies which are developing Metachromatic Leukodystrophy. Currently, Orchard Therapeutics has its Metachromatic Leukodystrophy drug candidates in the most advanced stage of clinical development.
Metachromatic Leukodystrophy (MLD) Emerging Drugs Covered in the report include:
- OTL-200: Orchard Therapeutics
- TAK-611: Takeda
And many more
Some of the key companies in the Metachromatic Leukodystrophy (MLD) Therapeutics Market include:
- Denali Therapeutics
- Orchard Therapeutics
- Homology Medicines
- Passage Bio
- ArmaGen Technologies
- Magenta Therapeutics
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:
Table of Content
- Report Introduction
- Executive Summary
- Metachromatic Leukodystrophy Current Treatment Patterns
- Metachromatic Leukodystrophy – DelveInsight’s Analytical Perspective
- Therapeutic Assessment
- Metachromatic Leukodystrophy Late Stage Products (Phase-III)
- Metachromatic Leukodystrophy Mid-Stage Products (Phase-II)
- Early Stage Products (Phase-I)
- Pre-clinical Products and Discovery Stage Products
- Inactive Products
- Dormant Products
- Metachromatic Leukodystrophy Discontinued Products
- Metachromatic Leukodystrophy Product Profiles
- Metachromatic Leukodystrophy Key Companies
- Metachromatic Leukodystrophy Key Products
- Dormant and Discontinued Products
- Metachromatic Leukodystrophy Unmet Needs
- Metachromatic Leukodystrophy Future Perspectives
- Metachromatic Leukodystrophy Analyst Review
- Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Download Sample PDF to Explore the Key Offerings of the Report:
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Email: [email protected]
Request for Sample Copy of the Report at:
Other Trending Healthcare Reports By DelveInsight
“Metachromatic Leukodystrophy (MLD) Market Insights, Epidemiology and Market Forecast” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Metachromatic Leukodystrophy (MLD) market size and shares analysis in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
“Metachromatic Leukodystrophy (MLD) Epidemiology Forecast” report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Metachromatic Leukodystrophy (MLD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.